Plain-English translation of NCT06735118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new way to use MRI imaging to measure fat buildup in the liver. Researchers want to see if a newer, faster imaging method called MDixon Quant can better detect fatty liver disease in cancer patients who are receiving chemotherapy. The goal is to make it easier and faster for doctors to spot this side effect early.
Some cancer patients develop fatty liver disease as a side effect of chemotherapy. Currently, doctors measure liver fat using older methods that are slow and sometimes miss fat in parts of the liver. This trial exists to see if the new imaging method is faster, easier, and more accurate at catching this problem.
You likely qualify if…
You likely don't qualify if…
You will come to the hospital for MRI scans of your liver at different time points during or after your cancer treatment. The researchers will use the new imaging method to measure how much fat is in your liver and compare it to traditional measurement methods. The study involves only imaging scans — no medications or invasive procedures.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Sponsor
Yunnan Cancer Hospital
Enrollment target
~120 participants
Started
December 2023
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lizhu Liu, Graduate
Ethics Committee of Yunnan Provincial Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.